Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SELL

SELL

Basics

Aliases:
This biomarker is also known as:
  • leukocyte-endothelial cell adhesion molecule 1,
  • hLHRc,
  • sL-selectin,
  • LECAM1,
  • LAM-1,
  • LEU8,
  • leukocyte surface antigen Leu-8,
  • pln homing receptor,
  • LYAM1,
  • lymph node homing receptor,
  • Leukocyte-endothelial cell adhesion molecule 1,
  • Lymph node homing receptor,
  • TQ1,
  • LAM1,
  • Leukocyte surface antigen Leu-8,
  • selectin L,
  • LSEL,
  • PLNHR,
  • Leukocyte adhesion molecule 1,
  • gp90-MEL,
  • Lyam-1,
  • CD62L antigen,
  • CD62 antigen-like family member L,
  • lymphocyte adhesion molecule 1,
  • LNHR,
  • Leu-8,
  • L-selectin,
  • CD62L,

View in BioMuta

Description…

From NCBI Gene and UniProtKB/Swiss-Prot: sL-selectin, also known as SELL, is a cell surface adhesion molecule that belongs to a family of adhesion/homing receptors. SELL mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes and promotes initial tethering and rolling of leukocytes in endothelia, facilitating their migration into secondary lymphoid organs and inflammation sites. SELL contains a C-type lectin-like domain, a calcium-binding epidermal growth factor-like domain, and two short complement-like repeats. Alternatively spliced transcript variants have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: SELL

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: One
QA State: Under Review

Overview

No additional data available.

Performance Comment

SELL is a member of a 28 autoantibody (AAb) classifier that was developed with a sensitivity of 80.8% and a specificity of 61.6% (AUC=0.756). The 28 autoantibodies are potential biomarkers for breast cancer both individually and as members of the classifier.

Lung

Attributes

Phase: Two
QA State: Curated

Overview

SELL has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010). A decreased level of SELL was seen in the serum of lung cancer patients compared to controls in this study.

Performance Comment

sL-selectin, also known as SELL, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.